Loading
Tiziana Life Sciences Ltd Stock: price and insider trades · United States
US·Mcap US$138.7M
2 insiders bought €906k of shares over the last 90 days, the latest by CERRONE GABRIELE M, filed 07 Aug 2026.
Tiziana Life Sciences Ltd: what insiders have been doing
This page follows insider dealings at Tiziana Life Sciences Ltd as filed with SEC (Form 4). In the past year (24 October 2025 to 24 October 2026), 7 filings came from 2 insiders.
Only purchases show up on the open market, 4 purchases in all worth €869k, filed by 2 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 senior executive and 1 chief executive among the declarants. The largest single trade was a purchase of €578k by Elrifi Ivor, published on 5 August 2026, equal to 0.50% of the market capitalisation.
The last purchase on record was published on 7 August 2026, which is 78 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (5,810 companies, median 19 filings), a count of 7 filings is below the norm. Over the whole record (from 2026), the tally stands at 4 purchases and no sales.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
7
Thresholds
n/a
Buy Volume
€869,328
4 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleIvor Elrifi3 buys
Gabriele M. Cerrone2 buys
Since the insiders bought
- -2.0%Entry US$1.01 · Close at T+30 US$0.99
- -1.0%Entry US$1.00 · Close at T+30 US$0.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Tiziana Life Sciences Ltd Strong Buy (bullish), based on 2 analysts. Average price target: US$8.02.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
US$1.09
Analyst consensus
2 analystsStrong buy
US$7.02Target US$8.02(+636%)US$9.02
Income statement
EBITDA-US$18.2M
Net income-US$18.4M0.0% margin
Valuation
PER (forward)-8.0x
P/Book14.4x
Beta0.44
Balance sheet & cash
Market capUS$138.7M
Total debtUS$456k
Free Cash Flow-US$12.9M
Debt / Equity877%
Profitability & ownership
ROE-924.3%
ROA-116.0%
% insiders47.6%
% institutions1.9%
Last declaration on 29 September 2026
Declarations7 total
1,050,000 sharesCOMMON STOCKSEC:0001213900-26-104755:0
15,000 shares@ US$1.110.013% mcap28.1% of flowCOMMON STOCKSEC:0001213900-26-086696:0
Canonical exit: 10 Sept 2026 (T+90)
83,807 shares@ US$0.970.061% mcap8.3% of flowCOMMON STOCKSEC:0001213900-26-085950:0
Canonical exit: 2 Nov 2026 (T+90)
237,616 shares@ US$1.000.18% mcap24.1% of flowCOMMON STOCKSEC:0001213900-26-085950:1
Canonical exit: 3 Nov 2026 (T+90)
667,000 shares@ US$1.000.50% mcap67.6% of flowCOMMON STOCKSEC:0001213900-26-085710:0
Canonical exit: 1 Nov 2026 (T+90)
42,357 shares@ US$0.990.032% mcap71.9% of flowCOMMON STOCKSEC:0001213900-26-080880:0
15,000 sharesCOMMON STOCKSEC:0001213900-26-069424:0
7 of 7 declarations
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It is listed on NASDAQ under the ticker TLSA.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
